Your session is about to expire
← Back to Search
Retinal Imaging for Neurodegenerative Disease
N/A
Recruiting
Led By Sharon Sharon, MD FACS FASRS
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with neurodegenerative disease (MCI/ADPD/MS/HD)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 year
Awards & highlights
Study Summary
This trial will use OCTA to develop biomarkers for various neurodegenerative diseases.
Who is the study for?
This trial is for adults with or without neurodegenerative diseases like Alzheimer's, Parkinson's, Multiple Sclerosis, and others. It includes those with mild cognitive issues or traumatic brain injuries. People can't join if they've had certain eye surgeries (except cataract surgery) or have conditions that make it hard to get clear images of their eyes.Check my eligibility
What is being tested?
The study tests non-invasive imaging techniques to examine the retina and choroid in the eye. These include optical coherence tomography (OCT), OCT angiography (OCTA), and ultra-widefield fundus photography to find biomarkers for various neurodegenerative diseases.See study design
What are the potential side effects?
Since this trial involves non-invasive retinal imaging, there are minimal side effects expected. The main risks may include discomfort from bright lights during imaging or temporary vision disturbances after the procedures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a neurodegenerative condition like Alzheimer's or Parkinson's.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in average capillary flux index (CFI)
Change in average capillary perfusion density (CPD)
Change in average perfusion density (PD)
+6 moreSecondary outcome measures
Change in retinal vessel fractal dimension
Change in retinal vessel tortuosity
Change in retinal vessel width gradient
Trial Design
2Treatment groups
Experimental Treatment
Group I: ControlsExperimental Treatment1 Intervention
Controls will be recruited from the relatives/attendants of study participants or will be patients themselves and will not have a neurodegenerative disease diagnosis.
Group II: CaseExperimental Treatment1 Intervention
Patients with (MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)
Find a Location
Who is running the clinical trial?
University of EdinburghOTHER
453 Previous Clinical Trials
16,474,329 Total Patients Enrolled
1 Trials studying Down Syndrome
200 Patients Enrolled for Down Syndrome
Tan Tock Seng Hospital in SingaporeUNKNOWN
Queens University of Belfast United KingdomUNKNOWN
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a neurodegenerative condition like Alzheimer's or Parkinson's.You have trouble following instructions or completing tests, or you have certain neurological or eye conditions that could affect taking pictures.Adults who do not have a brain disease that gets worse over time.I have had eye surgery, but not for cataracts.I have a neurodegenerative condition like Alzheimer's, Parkinson's, or MS.
Research Study Groups:
This trial has the following groups:- Group 1: Case
- Group 2: Controls
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants has the research team recruited for this project?
"Affirmative. The clinicaltrials.gov portal reveals that this medical experiment, which was first announced on July 20th 2017, is actively recruiting participants. To achieve the desired sample size of 1000 patients, only 1 site needs to be staffed."
Answered by AI
Are current enrollees being accepted into this research endeavor?
"Affirmative. Clinicaltrials.gov displays that this investigation, which was initially posted on July 20th 2017, is still open to participants. A total of 1000 patients will be invited from 1 medical centre."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger